Search clinical trials for: Encorafenib

Total 76 results

Pierre Fabre Medicament
European Organisation for Research and Treatment of Cancer - EORTC

Active, not recruiting

Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation. (COLUMBUS-AD)

Melanoma

Spain, Canada, Hungary, Italy, Belgium, Netherlands, Australia, Czechia, Greece, Brazil, Portugal, Serbia, Sweden, Norway, Germany, Argentina, Romania, Poland, United Kingdom, Austria, Switzerland, France, South Africa
Leiden University Medical Center
Pierre Fabre Laboratories

Recruiting

(Neo)Adjuvant BRAF/MEK Inhibition in pN1c Melanoma

Melanoma Stage III | In-Transit Metastasis of Cutaneous Melanoma

Netherlands
National Cancer Institute (NCI)

Recruiting

Encorafenib Plus Binimetinib for People With BRAF V600 Mutated Relapsed/Refractory HCL

Hairy Cell Leukemia

United States
Pierre Fabre Pharma GmbH
Pierre Fabre Pharma Austria; Pierre Fabre Pharma AG

Recruiting

Binimetinib Plus Encorafenib Real Life Investigation of Next Generation Melanoma Treatment (BERING)

Melanoma Stage IV | Melanoma Stage III

Austria, Germany, Switzerland
University Health Network, Toronto

Active, not recruiting

Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations (BEAVER)

Solid Tumor

Canada
Pfizer

Terminated

An Open-Label, Randomized, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard-dose and a High-dose Regimen in Patients With BRAFV600-mutant Melanoma Brain Metastasis (POLARIS)

Brain Metastases

United States, Belgium, Australia, Argentina, Italy
Pfizer
Pierre Fabre Laboratories

Terminated

Study of the Combination of Binimetinib and Encorafenib in Adolescent Patients With Unresectable or Metastatic BRAF V600-mutant Melanoma

Melanoma

Italy
Array BioPharma

Terminated

LGX818 in Combination With Agents (MEK162; BKM120; LEE011; BGJ398; INC280) in Advanced BRAF Melanoma (LOGIC)

Melanoma

Canada, Spain, Australia, Switzerland, Germany, United States
Pfizer

Recruiting

The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials

Solid Tumors

United States, Spain, Canada, Italy, Australia, Hungary, Netherlands, United Kingdom, Germany, Brazil, Korea, Republic of, Portugal, France, Japan, Israel, Russian Federation, Slovakia, Czechia
University of Utah
Verastem, Inc.

Recruiting

Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma (DETERMINE)

Melanoma

United States
Pierre Fabre Medicament

Withdrawn

Hepatic Impairment Study of Encorafenib in Combination With Binimetinib in BRAF Melanoma

Hepatic Impairment | Metastatic Melanoma | Unresectable Melanoma | BRAF V600 Mutation

Spain, Czechia, Italy
University of Heidelberg Medical Center
German Cancer Research Center; University Hospital Heidelberg; Array BioPharma; Coordinating Centre for Clinical Trials Heidelberg

Active, not recruiting

BRAF/MEK Inhibition in Relapsed/Refractory Multiple Myeloma (BIRMA) (GMMG-BIRMA)

Relapsed or Refractory Multiple Myeloma | Patients With BRAFV600 E or BRAFV600K Mutation

Germany
Array BioPharma

Terminated

Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma.

Locally Advanced Metastatic BRAF Mutant Melanoma

Australia, Canada, Netherlands, United States
Intergroupe Francophone de Cancerologie Thoracique

Recruiting

ENCOrafenib With Binimetinib in bRAF NSCLC (ENCO-BRAF)

Non Small Cell Lung Cancer | BRAF V600E

France
Pfizer

Active, not recruiting

An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

United States, Spain, Netherlands, Korea, Republic of, Italy
Pfizer
Ono Pharmaceutical Co. Ltd; Pierre Fabre Laboratories

Completed

A Relative Bioavailability Study Evaluating Two New Encorafenib Formulations (ERBA)

Healthy

United States
Memorial Sloan Kettering Cancer Center
Array BioPharma

Completed

A Study of Binimetinib and Encorafenib in Advanced BRAF Mutant Cancers

Advanced BRAF Mutant Cancers

United States
Pierre Fabre Medicament

Completed

Phase 1 Safety Study of Encorafenib in Chinese Patients With Advanced Metastatic BRAF V600E Mutant Solid Tumors (OCEANI)

Melanoma | BRAF V600E Unresectable or Metastatic Melanoma | BRAF V600E Metastatic NSCLC

China
Pfizer

Recruiting

A Study to Learn About the Study Medicine Called PF-07799544 in People With Advanced Solid Tumors

Glioma | Melanoma | Colorectal Cancer | Brain Neoplasms | Non-Small Cell Lung Cancer | Thyroid Cancer | Malignant Neoplasms

Canada, United States
CCTU- Cancer Theme
Pierre Fabre Medicament

Not yet recruiting

Perioperative Encobini in BRAFV600 Mutant Stage III (B/C/D) or Oligometastatic Stage IV Melanoma (PREMIUM)

Melanoma | Cancer

United Kingdom
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI); Pfizer

Terminated

Study of Binimetinib With Encorafenib in Adults With Recurrent BRAF V600-Mutated HGG (BRAF)

Glioblastoma | High Grade Glioma | Gliosarcoma | Anaplastic Astrocytoma | Anaplastic Pleomorphic Xanthoastrocytoma | BRAF V600E | BRAF V600K

United States
Gruppo Oncologico del Nord-Ovest
Merck Sharp & Dohme LLC; Pierre Fabre Laboratories

Recruiting

Phase II Study of ctDNA-guided Encorafenib Plus Cetuximab Retreatment in Patients BRAF V600E Mutated mCRC (BRICKET)

Colorectal Cancer

Italy
Grupo Español Multidisciplinar de Melanoma
Pierre Fabre Medicament; MFAR

Active, not recruiting

Encorafenib and Binimetinib Before Local Treatment in Patients With BRAF Mutant Melanoma Metastatic to the Brain (EBRAIN-MEL)

Metastatic Melanoma | Brain Metastases

Spain
Pierre Fabre Pharma GmbH
iOMEDICO AG; Pierre Fabre Pharma Austria; Pierre Fabre Pharma AG

Recruiting

BRAF Inhibitor Encorafenib And Cetuximab Real Life Investigation of Next Generation CRC Treatment (BERING-CRC)

Metastatic Colorectal Carcinoma

Austria, Germany
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Terminated

Binimetinib and Encorafenib for the Treatment of Pancreatic Cancer in Patients With a Somatic BRAF V600E Mutation

Metastatic Pancreatic Carcinoma | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Recurrent Pancreatic Carcinoma | Locally Advanced Pancreatic Carcinoma

United States
AIO-Studien-gGmbH
Universitätsklinikum Hamburg-Eppendorf; Merck Serono GmbH, Germany; Pierre Fabre...

Recruiting

Neoadjuvant Encorafenib, Binimetinib and Cetuximab for Patients With BRAF V600E Mutated/pMMR Localized Colorectal Cancer (NeoBRAF)

Colorectal Cancer | Colon Cancer | BRAF V600 Mutation | BRAF V600E | Localized Cancer

Germany
M.D. Anderson Cancer Center
Eli Lilly and Company; BioMed Valley Discoveries, Inc

Recruiting

Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination with Cetuximab and Encorafenib in Patients with Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed Therapy

Metastatic Colorectal Cancer

United States
Pierre Fabre Medicament
Pfizer; Merck KGaA, Darmstadt, Germany; Ono Pharmaceutical Co. Ltd

Completed

Encorafenib, Binimetinib and Cetuximab in Subjects With Previously Untreated BRAF-mutant ColoRectal Cancer (ANCHOR-CRC)

BRAF V600E-mutant Metastatic Colorectal Cancer

France, Italy, United States, Spain, United Kingdom, Belgium, Austria, Japan, Netherlands
M.D. Anderson Cancer Center

Recruiting

Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases

Metastatic Melanoma | Clinical Stage IV Cutaneous Melanoma AJCC v8 | Pathologic Stage IV Cutaneous Melanoma AJCC v8

United States
K-Group, Beta, Inc., a wholly owned subsidiary...
Pfizer

Recruiting

ZN-c3 in Adult Participants With Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

Spain, Australia, United States, Italy, Germany, Poland, Hungary
Prof. Dr. med. Dirk Schadendorf

Completed

Encorafenib + Binimetinib + Pembrolizumab in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma (IMMU-TARGET)

Malignant Melanoma

Germany
Federation Francophone de Cancerologie Digestive
Merck Sharp & Dohme LLC; Pierre Fabre Laboratories

Recruiting

Encorafenib Plus Cetuximab in a Neoadjuvant Setting in Patients With BRAF Mutation Localised Colon or Upper Rectum Cancer (NEORAF)

Colorectal Cancer | BRAF V600E Mutation Positive

France
Curegenix Inc.
Merck Sharp & Dohme LLC

Recruiting

CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596)

Solid Tumors | GI Cancer

United States, Taiwan
Peter MacCallum Cancer Centre, Australia

Recruiting

Encorafenib, Binimetinib and Palbociclib in BRAF-mutant Metastatic Melanoma CELEBRATE (CELEBRATE)

Melanoma | Metastasis

Australia
H. Lee Moffitt Cancer Center and Research Institute
Pfizer

Recruiting

Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma

Melanoma Stage IV | BRAF V600 Mutation | Melanoma Stage III

United States
European Organisation for Research and Treatment...

Active, not recruiting

Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib (EBIN)

Stage IV Melanoma | Unresectable Stage III Melanoma

France, Denmark, Spain, Finland, Italy, Germany, Poland, United Kingdom, Netherlands
Pfizer
Merck Sharp & Dohme LLC

Active, not recruiting

A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma

Melanoma

France, United States, Hungary, Italy, Spain, Czechia, Belgium, Germany, New Zealand, Canada, Austria, Israel, Poland, Russian Federation, Turkey, Switzerland, South Africa, Slovakia, United Kingdom, Ukraine, Brazil, Argentina, Bulg... and more
Dr. Ronnie Shapira

Not yet recruiting

Overcoming Primary Resistance to Immunotherapy in Metastatic Melanoma (MK3475-C01)

Metastatic Melanoma | Malignant Melanoma | Immunotherapy | Malignant Melanoma Stage IV | BRAF V600E
Pfizer

Active, not recruiting

Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)

Carcinoma, Non-Small-Cell Lung

United States, Belgium, Taiwan, Australia, United Kingdom
Vall d'Hebron Institute of Oncology

Not yet recruiting

Combination Therapy for BRAF-V600E Metastatic CRCm (BRAVE)

Metastatic Colorectal Cancer
H. Lee Moffitt Cancer Center and Research Institute

Recruiting

Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma

Skin Cancer | Melanoma (Skin) | Skin Carcinoma | Skin Melanoma

United States
Pierre Fabre Medicament

Active, not recruiting

Phase II Study Investigating the Combination of Encorafenib and Binimetinib in BRAF V600E Mutated Chinese Patients With Metastatic Non-Small Cell Lung Cancer (OCEANII)

Non-Small Cell Lung Cancer

China, Taiwan
Pfizer

Completed

Comparative Effectiveness of Targeted Therapies in BRAF Positive Metastatic Melanoma in the US (OCEANMIST)

Melanoma

United States
Baxalta now part of Shire

Completed

Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) Subjects

Primary Immunodeficiency Diseases (PID)

United States
Baxalta now part of Shire

Completed

Safety and Efficacy Study of a 10% Intravenous Immune Globulin Solution in Subjects With Primary Immunodeficiency Disorders

Primary Immunodeficiency Diseases (PID) | Immune Thrombocytopenic Purpura (ITP) | Kawasaki Syndrome

United States
Erasca, Inc.

Active, not recruiting

A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies (HERKULES-3)

Metastatic Colorectal Cancer | Metastatic Pancreatic Ductal Adenocarcinoma

United States
UNICANCER
Merck Sharp & Dohme LLC; Pierre Fabre Medicament; European Association of Dermato...

Active, not recruiting

Binimetinib Encorafenib Pembrolizumab +/- Stereotactic Radiosurgery in BRAFV600 Melanoma With Brain Metastasis (BEPCOME-MB)

Brain Metastases | Malignant Melanoma | BRAF V600 Mutation

France
Pfizer

Active, not recruiting

PF-07284892 in Participants With Advanced Solid Tumors

Solid Tumor

United States
Jason J. Luke, MD
Bristol-Myers Squibb

Terminated

Safety and Efficacy in Participants With Metastatic BRAF-mutant Melanoma Treated With Encorafenib With and Without Binimetinib in Combination With Nivolumab and Low-dose Ipilimuma (QUAD01)

Melanoma

United States
Pfizer
Merck Sharp & Dohme LLC

Active, not recruiting

A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced Melanoma (PORTSIDE)

Melanoma

Spain, United Kingdom, Germany, Italy, Poland, Czechia, Slovakia

Search clinical trials for: Encorafenib

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bulgaria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations